News
Boston Scientific has raised its 2025 profit outlook to between $2.95 and $2.99 per share amid strong Q2 performance in its cardiovascular unit, driven in large part by the uptake of its Farapulse ...
Following a period of relative dormancy, research and development in the Alzheimer’s disease space is booming. And mounting attention, both in the development of disease modifying therapies (DMTs) and ...
Roche’s Elecsys pTau181 test has secured CE Mark approval, marking a development in ruling out Alzheimer's disease.
The European Commission (EC) has approved a €403m ($473.3m) public funding package to support medical device innovation in the bloc.
Nestmedic has chosen Curavit Clinical Research to spearhead the US clinical study of the remote prenatal monitoring solution, PregnaOne.
Despite its clinical importance, the global ICP monitoring market remains small, slow-growing, and resistant to disruption.
Healthcare investment company ARCHIMED’s affiliate is set to acquire ZimVie for an enterprise value of around $730m.
The implications of medical device regulations on market entry strategies are profound. Credit: Doidam 10/Shutterstock.com. The medical devices industry is always undergoing significant regulatory ...
Medtronic’s MiniMed 780G system has received European CE Mark approval to expand the indications for use by people aged two years and above, during pregnancy, and for those with type 2 ...
Life sciences venture capital (VC) firm Omega Funds has closed its eighth fund, with capital commitments totalling $647m.
The US Court of Appeals has overturned a $106.5m ruling wherein a California court jury found that Medtronic infringed on a heart valve replacement method developed by Colibri Heart Valve.
DeepQure has secured approval from South Korea's MFDS for the trial of its HyperQure, aimed at treating atrial fibrillation (AF).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results